Massive study tracks malaria Vaccine's Real-World shield for kids

NCT ID NCT03855995

Summary

This large study monitored the safety and real-world performance of the RTS,S malaria vaccine after it was introduced into routine childhood immunization programs in sub-Saharan Africa. Researchers followed over 77,000 young children, comparing health outcomes between those who received the vaccine and those who did not. The goal was to confirm the vaccine's safety profile and measure how well it prevented malaria, severe illness, and hospitalizations in everyday use.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Kintampo, Ghana

  • GSK Investigational Site

    Navrongo, Ghana

  • GSK Investigational Site

    Kisumu, 4 0100, Kenya

  • GSK Investigational Site

    Kisumu, 40100, Kenya

  • GSK Investigational Site

    Chikwawa, Malawi

  • GSK Investigational Site

    Mangochi, Malawi

Conditions

Explore the condition pages connected to this study.